Abstract 239P
Background
Oral cancer surgery includes radical resections of the mandible and tongue, affecting the functional swallowing outcomes. However, risk factors and swallowing outcomes are not the same for all subsites of oral cancer. The present study aimed to assess the difference in patient-reported swallowing function and quality of life after primary surgical resection in tongue vs bucco- alveolar complex (BAC) malignancies.
Methods
Study included oral cancer patients requiring mandibulectomy for BAC subsite and at least hemi-glossectomy for tongue, all reconstructed with pedicle flaps at our institute from Dec 2019 to Dec 2021. The Sydney Swallow Questionnaire (SSQ) and Functional oral intake scale (FOIS) were used to assess swallowing outcomes after six months DFS. WHO BREF questionnaire was used to assess health-related quality of life.
Results
The final analysis included 66 patients. The median age was 48 yrs and majority are males (92.4%). BAC constituted 63.6%, and tongue lesions were 36.4%. Tumours with cT3 and T4 are 59% of BAC and 46% of tongue lesions. In BAC, 85% underwent segmental mandibulectomy, and 87% of tongue lesions were treated with hemiglossectomy. 85.7% of BAC and 92% of tongue lesions received adjuvant radiation. Trismus and xerostomia were present in 71.4%, 85% in BAC and 50%, 75% in tongue lesions, respectively. The mean SSQ score was (282.6, SD= 95), (222.5, SD=96) BAC and tongue, respectively. Advanced T stage (p=0.07), Multimodality treatment (p=0.01), lymphedema (p=0.03), Trismus (p=0.01), Dysgeusia (p=0.01), xerostomia (p=0.01) in BAC lesions. Advanced T stage (p=0.007), Multimodality treatment (p=0.04), lymphedema (p=0.03), Dysgeusia (p=0.01) in tongue lesions are associated with poor outcomes. Almost 88% of BAC lesions required special food preparation for swallowing (FOIS 5). However, only 16.7% of tongue lesions required special preparation. There is a trend toward better health-related quality of life (HRQOL) in tongue lesions.
Conclusions
There is a difference in swallowing results between tongue and BAC cancers. Tongue lesions had more reasonable swallowing outcomes. However, overall, HRQOL is comparable between both subsites.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract